We are examining the long-term safety of asciminib in patients with certain types of leukemia who have completed a previous study. This trial aims to see if continued treatment is beneficial for these patients.
We are testing the safety and tolerability of a new monoclonal antibody, VRDN-001, in people with thyroid eye disease. This study involves receiving intravenous infusions to see how well the treatment is tolerated.
We are studying a new treatment called ABBV-CLS-484 for people with advanced tumor cancer. The trial will explore its effects alone and in combination with other therapies.
We are comparing the effectiveness and side effects of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumors. This study aims to improve treatment options and patient quality of life.
We are investigating a new 21-valent vaccine for healthy infants starting at 2 months old. The study aims to see if it works as well or better than the current vaccine in protecting against pneumonia.
We are investigating the safety of a new drug, GB-0895, in patients with mild to moderate asthma and those with COPD. This study aims to understand how well the drug is tolerated in these groups.
We are studying a new T cell therapy for people with active systemic lupus erythematosus to see if it is safe and effective. This research aims to understand how it affects disease activity and overall health.
We are investigating if switching to oral antibiotics after one week is as effective as continuing intravenous treatment for pyogenic vertebral osteomyelitis. This study will also assess safety, hospital stays, and quality of life for patients.
We are testing a new vaccine for adults with hepatitis B to see if it is safe and how well it boosts the immune response. The study will also check if it helps reduce the virus in the body.
We are exploring how multiple sclerosis impacts patients physically while ensuring they can continue receiving ocrelizumab treatment. This study also looks at the safety and tolerability of the medication.
We are assessing how the oral medication ABBV-453 affects adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The study focuses on understanding its side effects and how it moves through the body.
We are studying a new treatment for patients with locally advanced or metastatic solid tumors to see if it is effective and safe. This trial will help us understand how well it works and its relationship with tumor characteristics.
We are investigating how effective and safe iodine-based contrast agents are in enhancing mammograms and breast MRIs. This study aims to improve imaging quality for women undergoing these tests.
We are investigating whether a shorter course of antibiotics is safe and effective for treating left-sided infectious endocarditis caused by specific bacteria. This study also looks at the potential cost benefits of this accelerated treatment.
We are testing a new treatment for patients with systemic lupus erythematosus that has not responded to standard therapies. The goal is to see if this new approach can provide better outcomes.
We are investigating how dapagliflozin affects immune activity and kidney function in patients with Membranous Nephropathy. This study may help us understand its potential benefits for managing this condition.
We are investigating whether metformin can improve muscle and overall function in patients with Myotonic Dystrophy Type I. The study will also assess the safety of metformin and its effects on quality of life.
We are investigating whether ruxolitinib can improve movement and muscle function in patients with Inclusion Body Myositis. The study also looks at safety and quality of life for participants.
We are studying a new treatment for men with advanced prostate cancer to see if it is safe and effective. This trial includes men who have been treated before and those who have not.
We are evaluating a new treatment called TERN-701 for individuals with chronic myeloid leukemia. The study aims to assess its safety and how well it works compared to existing options.